Spruce Biosciences recently announced that its candidate drug TA-ERT for Sanfilippo syndrome type B (also known as MPS IIIB) received positive feedback during a Type B meeting with the U.S. Food and Drug Administration (FDA).
Show original
The meeting focused on discussing the clinical development plan for the drug. Both parties reached an important consensus on the subsequent trial protocol, laying a solid foundation for advancing the research and development process of TA-ERT.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
Data: Hyperliquid platform whale currently holds $2.887 billions, with a long-short ratio of 0.99
Chaincatcher•2026/03/02 13:03
Bitget adds stock contracts for TSMC TSM, Walmart WMT, Costco COST, and others
Odaily星球日报•2026/03/02 13:03
Trending news
MoreCrypto prices
More
Bitcoin
BTC
$66,037.73
-0.27%
Ethereum
ETH
$1,941.48
-1.50%
Tether USDt
USDT
$0.9999
-0.02%
BNB
BNB
$622.68
+0.30%
XRP
XRP
$1.35
-1.34%
USDC
USDC
$1
+0.02%
Solana
SOL
$83.67
-1.28%
TRON
TRX
$0.2815
+0.18%
Dogecoin
DOGE
$0.09153
-1.39%
Cardano
ADA
$0.2713
-1.70%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now